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Abstract: Surface plasmon resonance (SPR) is a label-free detection method which has 
emerged during the last two decades as a suitable and reliable platform in clinical analysis 
for biomolecular interactions. The technique makes it possible to measure interactions in 
real-time with high sensitivity and without the need of labels. This review article discusses 
a wide range of applications in optical-based sensors using either surface plasmon resonance 
(SPR) or surface plasmon resonance imaging (SPRI). Here we summarize the principles, 
provide examples, and illustrate the utility of SPR and SPRI through example applications 
from the biomedical, proteomics, genomics and bioengineering fields. In addition, SPR 
signal amplification strategies and surface functionalization are covered in the review. 
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1. Introduction 
Numerous strategies for protein labeling have been developed that allow the characterization of 
proteins regarding their structure, folding or interaction with other proteins [1,2]. Labeling strategies are 
used to bring about the covalent attachment of reporter tags, such as biotin, radioisotopes, fluorophores, 
or enzymes, to the target biomolecules (i.e., proteins and nucleotides) to quantitatively assess binding 
among biomolecules [3,4]. In addition, the use of molecular labels can cause steric hindrance or change 
structural configurations, affecting the labelled molecules’ affinities for their target biomolecules, which 
is a major challenge. Label-free detection eliminates the need for specialized tags or dyes, thereby 
allowing the sensitive measurement of target analytes and enabling the use of native biomolecules 
suitable for biologically relevant approaches. In the past few decades, a variety of optical biosensor 
methods have been developed, including surface plasmon resonance (SPR) [5], quartz crystal 
microbalance (QCM) [6], and ellipsometry [7]. Among the various optical sensing methodologies, the 
SPR-based system is a representative type of label-free technique for monitoring biomolecular 
interactions in real-time. 
Since it was first introduced in the early 1990s, SPR has been proven to be one of the most  
powerful technologies to determine specificity, affinity and kinetic parameters during the binding  
of macromolecules in many bonds types, including protein-protein [8,9], protein-DNA [10,11],  
enzyme-substrate or inhibitor [4,12], receptor-drug [13,14], lipid membrane-protein [15,16],  
protein-polysaccharide [17], cell or virus-protein [18–20], among others. This optical technique measures 
the refractive index changes in the vicinity of thin metal layers (i.e., gold, silver, or aluminum films) in 
response to biomolecular interactions. Before a sample solution flows across the SPR surface, capturing 
agents, such as antibodies, enzymes, peptides and DNAs are immobilized on the surface. The changes in 
the SPR angle, which is the angle of minimum reflectivity, can be determined by varying the incidence 
angle and recording the reflected light intensity during the biological binding reactions between various 
biomolecules. So far, numerous studies have advanced the potential of SPR sensors by increasing the 
effectiveness of the technique [21–23]. Accordingly, the possible fields of application of SPR technology 
have expanded to biomedical, environmental and industrial areas. As has been extensively and intensively 
documented in the literature, SPR is an acceptable method for disease diagnosis, drug discovery, foodborne 
pathogen detection, and so on [24,25]. Above all, the application of SPR for biomedical purposes is 
remarkable. So far, various types of SPR measurement systems have been developed for the monitoring 
of chemical and biological species via the basic theory of SPR detection [26–28]. Here we review recent 
advances in SPR biosensing, with a particular focus on practical applications of SPR-type biosensors, 
describing their usefulness and challenges for bioassays. 
2. Operating Principle of SPR Biosensors 
2.1. General Principle of SPR 
Surface plasmon resonance occurs when a photon of incident light hits a metal surface (typically a 
gold surface). At a certain angle of incidence, a portion of the light energy couples through the metal 
coating with the electrons in the metal surface layer, which then move due to excitation. The electron 
movements are now called plasmon, and they propagate parallel to the metal surface. The plasmon 
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oscillation in turn generates an electric field whose range is around 300 nm from the boundary between 
the metal surface and sample solution [29]. In a commercial SPR biosensor configuration, incident light 
is employed by using a high-reflective index glass prism in the Kretschmann geometry of the attenuated 
total reflection (ATR) method (Figure 1). The defined SPR angle, at which resonance occurs, on the 
conditions of the constant light source wavelength and metal thin surface, is dependent on the refractive 
index of the material near the metal surface. Consequently, when there is a small change in the reflective 
index of the sensing medium (e.g., through biomolecule attachment), plasmon cannot be formed. 
Detection is thus accomplished by measuring the changes in the reflected light obtained on a detector. 
In addition, the amount of surface concentration can be quantified by monitoring the reflected light 
intensity or tracking the resonance angle shifts. Typically, an SPR biosensor has a detection limit on the 
order of 10 pg/mL. 
 
Figure 1. Concept of a surface plasmon resonance (SPR) biosensor: (A) Kretschmann 
geometry of the ATR method; (B) spectrum of reflected light before and after refractive 
index change; (C) analyte-biorecognition elements binding on SPR sensor surface and  
(D) refractive index changes caused by the molecular interactions in the reaction medium. 
Adapted from [30]. 
In SPR biosensors, probe molecules are firstly immobilized on to the sensor surface. When the 
solution of target molecules is flown into contact with the surface, a probe-target binding via affinity 
interaction occurs, which consequently induces an increase in the refractive index at the SPR sensor 
surface (Figure 1D). In SPR experiments, resonance or response units (RU) are used to describe the 
signal change, where 1 RU is equivalent to a critical angle shift of 10−4 degree. At the start of the 
experiment whereas probe target interactions have not occurred, the initial RU value corresponds to the 
starting critical angle. The change in refractive index Δnd arisen within a layer of thickness h can be 
calculated as 
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Δnd = (dn/dc)vol ΔΓ/h (1)
where (dn/dc)vol is the increase of refractive index n with the volume concentration of analyte c, and ΔΓ 
is the concentration of the bound target on the surface [31]. The change in the refractive index is tracked 
by the coupling of incident light into a propagating surface plasmon (PSP) on a gold surface in real time. 
Accordingly, the rate of association (kon) during association phase, the rate of disassociation (koff) when 
target molecules is removed from the continuous flow by buffer washing, and the association rate 
constant (ka) and dissociation rate constant (kd) can be determined by SPR evaluation of binding kinetics. 
The parameter related to the refractive index can also be used to detect and quantify the target molecules 
bound to a known probe immobilized on the sensor surface. The limit of detection (LOD) in the SPR 
experiment depends on a number of factors including the molecular weight, optical property and binding 
affinity of target-probe molecules as well as the surface coverage of the probe molecule. 
2.2. SPR Imaging Principle 
In high-throughput screenings and multiplex analyses, a combination of protein arrays and the SPR 
technique would provide an excellent alternative and label-free method in comparison with the existing 
methods that require kinetic data. However, standard SPR biosensor instrumentation, with 3–4 flow cells 
on a single sensor chip, acts more as a hindrance than an aid to high-throughput screening (HTS) 
applications. To overcome this obstacle, a modified version of SPR design, called SPR imaging (SPRI), 
has been developed to simultaneously process hundreds or thousands of samples. SPR imaging systems 
using rapid optical arrays have potential applications in the high-throughput screening of drugs and 
biomarkers, as well as clinical diagnosis through their use in multi-array detection systems. SPR imaging 
technology represents an important step forward to SPR analysis. Not eliminating the sensitive  
label-free method, SPRI’s additional value lies in its capability to visualize a whole biochip via a CCD 
camera. The improved design enables biochips to be prepared in an array format, in which each array 
spot can provide a wealth of SPR information simultaneously. As shown in Figure 2, in an SPRI system, 
a coherent polarized light beam is used instead of polychromatic light. This change helps expand the 
light cover on a larger area of the sensing surface. The reflected light is captured by a charge-coupled 
device (CCD) camera for further imaging analysis. The high resolution CCD camera provides images 
across the array format in real-time with up to hundreds of active spots. Captured images that show local 
changes at the chip surface can provide detailed information on molecular binding, interactions or kinetic 
processes. Unlike conventional SPR, the measurement conducted by SPRI is stringently performed at a 
constant wavelength and a constant angle [32]. Thus, changes in reflected light intensity are proportional 
to any variation of the refractive index near the metal surface [33]. 
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Figure 2. General principle of surface plasmon resonance imaging (SPRI). (Left) The 
instrumentation of an SPR imaging system: The light source is a quartz tungsten-halogen 
lamp; the light is delivered through a liquid light guide to a goniometer arm, collimated by 
lenses, and passed through a narrow interference filter and a polarizer. A p-polarized and 
monochromatic light beam is then focused directly onto a prism coupler. The reflected light 
from the gold surface is captured by a monochromatic CCD camera. L2, L3 are lenses 
positioned in front of CCD for higher quality images. The images could be digitally stored 
using a B/W frame grabber and further analyzed using photography software; (Right) The 
analyte-ligand interaction shifts the SPR curve towards a higher angle (red to orange).  
Due to the measurement confinements (fixed wavelength and angle of incidence θ), changes 
in the reflectivity (Δ%R) at a single spot of the array can be simultaneously detected. 
Adapted from [32]. 
3. Applications of SPR-Based Biosensors 
3.1. Biomedical Applications 
SPR biosensing appears to be one of the most powerful approach for monitoring of affinity binding 
of biomolecules, and primary screening of druggable molecules. SPR-type sensors are increasingly used 
to study a variety of biological entities, such as DNAs, RNAs, proteins, carbohydrates, lipids, and cells 
in the field of biomedical research. In this subsection, several examples of biomedical applications of 
SPR technology including interaction analyses, conformational change studies, and mutation detection 
are described. 
3.1.1. Interaction Analyses 
A wide range of applications has been developed for the use of SPR biosensors in the biomedical 
field. First of all, SPR has been used as a powerful tool to study interactions between biomolecules based 
on affinity binding analysis of a variety of bonds, including antibody-antigen [34], ligand-receptor 
kinetics [35–42], enzyme-substrate reaction [4,43] and epitope mapping [44]. Real-time monitoring of 
DNA manipulation such as hybridization kinetics, enzymatic modifications, and DNA strand separation 
using SPR biosensors was earlier introduced in 1995 by Nilsson et al. [45]. The advent of click chemistry 
has allowed scientists to design DNA analogs with novel properties unseen in nature as well as improved 
stability, functionality and binding characteristics that can be utilized to develop innovative therapeutic 
agents or new tools for diagnostics. Artificial nucleosides with unusual structural features, such as 
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peptide nucleic acid (PNA), locked nucleic acid (LNA), hexitol nucleic acid (HNA) and phosphoramidates 
morpholino (MORF) oligomers have proven advantages over functional nucleic acids (aptamers and 
DNAzymes) in terms of denaturation and biodegradation stability in body fluids. In SPR studies, 
aptamers are considered promising recognition elements with good chemical stability, high selectivity 
and high affinity toward their targets, and they are easily chemically modified. Aptamers offer more 
advantages than antibodies. SPR detection was employed in the selection of an RNA aptamer for human 
influenza [46], and aptamer-based SPR analyses were successfully applied in the detection of human 
IgE [47], C-reactive protein (CRP) [48] and the HIV-1-trans-activating (Tat) protein [49], and RBP4 
(retinol binding protein 4), a diabetes biomarker [50]. There is another branch of DNA analogs that are 
designed to target single-stranded DNA and RNA with high affinity and specificity; they are 
conformationally restricted DNA analogs, such as PNA, LNA, HNA and MORF. These molecules have 
great uses in radiopharmaceutical applications. Many researchers have utilized these artificial molecules 
to study DNA hybridization [51,52], pathogen DNA detection, single-nucleotide polymorphisms  
(SNPs) [53] and miRNA detection. A thorough review of the use of these DNA analogs as recognition 
elements in SPR-based sensing can be found elsewhere [54]. 
3.1.2. Conformational Change Studies 
In addition, the SPR signal intensity has been shown to be strongly affected by optical thickness 
changes in the sensor metal film, as well as by refraction index changes taking place near the metal 
surface (~200 nm). As a protein molecule undergoes a structural change, those optical indicators are also 
affected and can be monitored by SPR biosensors. Nevertheless, the SPR technique is often used as a 
complementary method to verify conformational changes study rather than as a primary technique. This 
application of the SPR technique has been used to monitor structural transition in protein-small molecule 
interactions [12], proteins under diverse environmental conditions [55,56] or impacts on apoptosis 
inducers [57]. In an attempt to detect protein conformational changes, in 2005, Kim et al. developed an 
antibody chip with conformational specificity to the Bax protein, a pro-apoptotic member of the Bcl-2 
family of proteins, which plays a pivotal role in the mitochondrial pathway for apoptosis [57]. Bax 
conformational change was first induced by the administration of an apoptosis inducer, TNF-related 
apoptosis-inducing ligand (TRAIL) and then measured by SPRI. The results indicated that only 
structurally altered Bax gave visible SPR images, while intact Bax seldom showed any data. 
3.1.3. Mutation Detection 
Another extension of SPR-based detection applications is its use in point mutation detection by 
combining SPR with other conventional techniques. For example, an SPR biosensor was utilized for the 
detection of point mutation using polymerization extension reaction [58]. In this experiment, the capture 
DNA and probe complementary DNA were coated by a natural complement, and PCR reaction was 
carried out directly on-chip. Only wild type DNA showed signal boosting by PCR, while mutant DNA 
showed no SPR signal amplification. Mutation in protein molecules has also been studied using the SPR 
technique [59]. The DNA-binding capability of tumor protein p53 was evaluated. This protein is the 
“master switch” for the control of cell proliferation, whose mutation causes genetic alterations in human 
cancers. DNA was immobilized on a BIACORE CM5 chip for the protein binding experiment. Purified 
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wild p53 and mutant p53 (R248W) were injected at a concentration of 100 nM and a flow rate of  
5 μL·min−1 for 6 min. The SPR data showed that the RU value of the mutant p53 protein was 4.7 times 
lower than that of wild p53 protein in response to 100 nM of each protein. Based on the fact that the SPR 
response is directly proportional to the amount of p53 protein that interacted with the consensus DNA 
coated on the gold thin film, the results obtained from SPR sensorgrams demonstrated that the wild p53 
protein could bind to the cognate DNA sequence while mutant p53 protein could not. 
3.2. High-Throughput Screening (HTS) 
The application extensions of SPR biosensors are not only limited to ligand-receptor interaction 
kinetics dynamic analyses; they are also used for drug discovery and drug development. There are 
several different formats of SPR biosensors, including the array format, multi-channel unit format, and 
SPR imaging format, which allow simultaneous and continuous detection to analyze the performance of 
hundreds to thousands of affinity binding events on a chip surface [60,61]. In SPR imaging, the incidence 
angle remains fixed, and the binding of biomolecules on a gold surface is measured as the change in 
reflectivity (or reflectance) in relation to the incident ray intensity, unlike SPR sensors that depend on 
the measurement of the absorption dip in the SPR angle or SPR wavelength. Despite the excellent 
benefits inherent in SPR technology, conventional propagating SPR biosensors have a serious limitation 
in their inability to support multiplex analysis, as less than four analyses with conventional SPR 
instruments make such parallel operations feasible. In contrast, SPR imaging technology using a  
multi-analyte biosensor permits a high-throughput approach, and it achieves a similar degree of 
sensitivity that achieved by conventional SPR biosensors (Figure 3) [62]. Thus, SPR imaging systems 
without any labeling requirements are more suitable for high-throughput screening (HTS), particularly 
in drug discovery, than any other optics-based detection techniques [63]. 
 
Figure 3. High-throughput drug screening using an SPR imaging protein chip system. The 
bright image indicates protein-protein interaction on a gold surface. Upon the binding of an 
inhibitor to the target protein, protein-protein interactions are disrupted, resulting in changes 
in SPR imaging signal intensity and a darker image. Adapted from [62]. 
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Krishnamoorthy et al. used a commercial SPR imaging instrument for the screening of kinetics and 
affinity constants of multiple biomolecular interactions simultaneously on a 6 × 4 microarray chip [64]. 
Ligands were serially diluted and spotted on the array following by an analyte sample injection. The 
SPR signal responses of 24 microarray spots were collected and used as data for the rates and affinity 
constant calculations. This method significantly reduces experiment time and cost in comparison with 
traditional approaches. In 2004, Maillart et al. described an SPR imaging system-based HTS approach 
for multiple analyses of interactions between the p53 transcription factor and its corresponding cis-acting 
DNA elements [65]. In 2007, Neuman et al. developed a method capable of detecting up to 9216  
target-ligand interactions on a single array [66]. 
3.3. Proteomics Researches 
In the field of proteomics, methods for the identification and analysis of biomarkers have gained more 
attention during recent years and have evolved rapidly. The identification and detection of disease 
biomarkers are important to foresee outbreaks of certain diseases, thereby avoiding surgery and other 
invasive and expensive medical treatments for patients. Thus, more research into discovering new 
biomarkers and new methods for faster and more accurate detection is needed. It is often difficult to 
detect and measure biomarkers because of their low concentrations and the complexity of their respective 
matrices. Therefore, it is hard to find and validate accurate screening methods suitable for clinical use. 
SPR has proven to be useful in biomarkers diagnosis due to its sensitivity, portability, obviation of large 
sample volumes, and capability of multiplexed detection. SPR biosensors have been successfully applied 
in detecting the biomarkers of numerous diseases, such as breast, ovarian, and pancreatic cancer, as well 
as cardiac and neurological diseases. 
3.3.1. Tumor-Associated DNA Markers 
In 2006, Li et al. developed a combination of surface hybridization, surface ligation and nanoparticle 
amplification for single-nucleotide polymorphism (SNP) genotyping in the BRCA1 gene [67], which  
is one of the two major genes (BRCA1 and BRCA2) reported to be connected to breast cancer 
susceptibility. These two tumor suppressor genes are involved in repairing the DNA double-strand 
breaks that are responsible for breast cancer. Mutations in these two genes can lead to instability of the 
human genome and can increase the risk of breast cancer for future patients from the age of 30 [68]. 
Therefore, the identification of BRCA mutations is of a great relevance for prospective interventions and 
treatments for breast cancer patients. By using nanoparticles with oligonucleotides complementary to 
the ligation probe DNA aiming at enhancing the SPR signal, single mismatches of BRCA1 were 
successfully detected at concentrations as low as 1 pM. The nanoparticles substantially help overcome 
the limitation of conventional SPR biosensors as, without amplification, the SPR direct detection limit 
is about 100 nM [69]. Label-free detection is simpler than label techniques; thus, a minimum detectable 
concentration for mutation analysis without labeling is relevant to optimize SPR methodology. Another 
commonly mutated gene in human cancers is the tumor suppressor p53 gene, whose main function is to 
mediate either cell cycle arrest or apoptosis. The loss of its activation is required for new oncogenic 
activities to promote tumorigenesis and drug resistance. It is reported that more than 50% of cancer 
patients show p53 gene mutation [70]. In another study, both wild-type and mutant p53 proteins at SPR 
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chip preimmobilized with consensus DNA and monoclonal antibody were detected [71]. The normal 
cell samples displayed significantly higher levels of wild-type p53; therefore, they showed higher 
affinity to the immobilized consensus double-stranded DNA. Meanwhile, the pre-immobilized 
monoclonal antibodies showed a specific affinity for the total p53. The difference between the SPR 
signals revealed the extent of p53 mutation. Low detection levels of wild-type p53 (10.6 pM) and total 
p53 (1.06 pM) were obtained due to the strong affinity of the consensus ds-DNA to the wild-type p53 
and that of the antibody to total p53. 
3.3.2. Disease-Related Protein Biomarkers 
In contrast to genetic markers, protein markers enable rigorous evaluation for clinical applications; 
therefore, protein-based assays are being developed. Because biomarkers in real blood samples exist in 
small concentration, this hinders the use of SPR biosensors. To overcome this, the aid of nanoparticles 
is needed for signal amplification. With the assistance of nanoparticles, researchers have been able to 
employ SPR in the detection of important biomarkers, such as total prostate-specific antigen (tPSA) [72], 
carbohydrate antigen 15-3 (CA15-3) [73], carcinoembryonic antigen (CEA) [74], C-reactive protein 
(CRP) [75], human epidermal growth factor receptor 2 (HER2) [76], estrogen receptor (ER) [14,77,78], 
progesterone receptor (PR) [79,80], etc. Figure 4 shows the schematic representation of PSA sandwich 
assay using PSA detection antibody-modified AuNPs [72]. By using 40 nm nanoparticles conjugated 
with the PSA antibody, a tPSA assay was performed on 75% human serum at a detection limit of  
0.29 ng·mL−1 (8.5 pM); tPSA was obtained in the 75% serum, which corresponds to 0.39 ng·mL−1 in 
whole serum with the SPR sensor. As this detection limit is lower than the threshold value for prostate 
cancer detection (2.5 ng·mL−1), it is possible to clinically diagnose prostate cancer with the developed 
immunoassay. Short assay time, repeated usability of the same sensor chip, ability to detect PSA in  
high serum concentration, and real-time testing enable the application of the optimized assay as a  
point-of-care device for clinical prostate cancer diagnosis and prognosis. 
 
Figure 4. Schematic representation of the PSA immunosensor based on PSA detection 
antibody-modified Au nanoparticles using surface plasmon resonance (SPR).  
For the PSA sandwich analysis, following PSA/tPSA bindingto the SPR sensor layer,  
1.5 μg·mL−1 PSA detection antibody or Anti-PSA antibody conjugated AuNPs  
(20 nm, 5.1 × 1010 nanoparticles/mL or 40 nm, 5.1 × 1010 nanoparticles/mL) was injected 
on the surface. Adapted from [72]. 
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CEA is the human cancer-associated antigen and serologic tumor biomarkers for diagnosis of 
colorectal, gastric and pancreatic cancers. The CEA level is a commonly used index in treatment after 
breast cancer surgery to identify recurrences. The normal CEA level is in the range of 3−5 ng/mL for a 
healthy woman. In 2006, Tang et al. used an SPR-based immunosensor that used protein A conjugated 
on a gold surface [74]. Next, a monoclonal anti-CEA antibody was coupled to protein A and prepared 
for CEA injections. The detection limit of 0.5 ng/mL was obtained for the purified CEA. C-reactive 
protein (CRP) is a principal blood serum biomarker for conventional inflammation and low-grade 
inflammation diagnosis. CRP is produced by the liver and rises in level whenever inflammation occurs 
throughout the body. Jung and coworkers used the CRP monoclonal antibody and an amide-linked (AL) 
N-hydroxysuccinimide (NHS)−dextran functionalized gold array surface in a spectral SPR system to 
detect C-reactive protein (CRP) in human sera with up to 120 human sera [75]. 
3.4. Cellular Analysis and Cell-Based Detection 
The SPR technique is not only advantageous due to its real-time and label-free imaging capabilities 
for dynamic changes at the surface but also for cellular changes, such as physiology, interactions at the 
cell-surface, and cell detection. The SPR technique enables the monitoring of cellular response, cellular 
adhesion and cellular products as well as the detection of cancer cells and bacteria cells .Upon receiving 
stimulation from reactive molecules, mammalian cells respond accordingly. The responses consequently 
induce SPR signal changes as interactions between cells and molecules occurs [81–83]. In a study in 
2007 by Yanase et al. [82], a large angle of resonance (AR) change in an SPR sensor was observed when 
RBL-2H3 rat mast cells and PAM212 cells (mouse keratinocyte cell lines) were cultured and activated 
on a sensor chip by an epidermal growth factor (EGF) or an antigen. In addition, the application of 
Mycalolide B and Toxin B (cell motility inhibitors) partially inhibited AR changes upon antigen 
stimulation; no cell movement or morphology changes were observed. These results suggest that AR 
changes reflect intracellular events other than cell-adhesion area size changes. SPR signal has been used 
to measure cell growth and size changes as well [84,85]. Exposure to non-isotonic stimulation can cause 
the cell volume to change. In particular, hypotonic stimulation results in SPR signal decrease, and the 
signal reverses to an equilibrium value after additional introduction of isotonic solutions. 
The SPR technique plays a major role in cancer cell detection. The first approach is based on cancer 
biomarker production employing monoclonal antibodies immobilized on the sensor surface. The second 
approach directly measures cellular response for quantitative analysis. Cancer cells are seeded directly 
onto the sensing surface and cultured. Next, solutions containing stimuli are flowed over the cells, and 
their response is measured in real time by SPR. This strategy has been successfully applied to detect and 
diagnose malignant tumors cells, such as Chinese hamster ovary cells without the use of immunological 
labels [86]. Liu et al. designed an SPR biosensing system with anti-VEGF antibodies immobilized on 
the surface and living SKOV-3 ovarian cancer cells cultured on the flow cell chamber ceiling [87]. The 
cancer cells, in the activity promoting blood vessels growth, started to produce VEGF. Subsequently, 
these induced VEGF formed specific bindings with the antibody downward on the chip surface, and the 
SPR signal was recorded. The designed system allows the real-time detection of VEGF with sensitivity 
in a linear dynamic range of 0.1–2.5 μg·mL−1. In 2006, our group described an integrative system using 
surface plasmon resonance imaging (SPRI) and a microwell gold protein chip [8]. With this system, we 
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were able to carry out recombinant E. coli culture and the detection and purification of the expressed 
proteins on the chip [88]. The whole procedure included protein induction on the microwell chip, E. coli 
cell lysation (by adding lysozymes), purification of expressed glutathione S-transferase-fused green 
fluorescent protein (GST-GFP) by affinity interaction with gold surface chip, and finally the detection 
of expressed proteins using the SPRI system. The microwell chip was constructed using PDMS 
elastomer affixed on a gold surface forming a 36-well chip with a 5 uL sample volume for each well. 
This all-in-one system shows benefits in terms of time and labor saving, as it allows researchers to carry 
out the entire tedious protein process on a single chip. Thus, high-throughput expression and purification 
of recombinant proteins in drug development could benefit from the use of our system. 
4. Immobilization of Biomolecules and Signal Amplification in SPR 
4.1. Immobilization of Biomolecules 
4.1.1. Covalent Coupling 
Covalent coupling is a commonly used immobilization method in the design of biosensor. To create 
covalent bonds, the reagents must activate the sensor chip surface to produce reactive species. Covalent 
coupling is then formed by the irreversible binding of reactive functional groups on the outside in a 
protein onto the activated surface. The chemical cross-linkers with spacer arms possess two functional 
groups; one is for covalent linkage to a surface, and the other functional group is for attachment to a 
biological molecule. Investigators have developed numerous covalent conjugation chemistries to 
produce protein-linker conjugates [89–91]. Several functional groups such as amine (-NH2), thiol (-SH), 
and aldehyde (-COOH) are most commonly used to covalently couple biomolecules to the solid support. 
Exposed amine (-NH2) groups on proteins can be coupled with various reactive intermediates such as 
N-Hydroxysuccinimide (NHS), aldehyde, and epoxide on the surface. In addition, thiol (-SH) groups 
present in cysteine residues can react and couple with a heterobifunctional crossliker such as a  
maleimide [92]. This thiol-maleimide reaction is a process that has been widely employed for the labeling 
of biomolecules. Another example of cysteine-mediated covalent conjugation is thiol-disulfide exchange 
coupling, which is usually derived by the coupling of two thiol groups [93]. Such covalently  
coupled-disulfide bonds are reversibly converted to thiols in the presence of reducing agents including 
dithiothreitol (DTT). Covalent coupling offers a stable, easy and ligand modification-free method for 
SPR surface functionalization. Nevertheless, in some cases, there are some drawbacks of the use of 
covalent coupling of biomolecules on a chemically-modified surface. First, covalent immobilization may 
involve chemical modification on the active sites of proteins which can potentially affect the  
analyte-binding activity. Second, the reactive functional groups can be blocked by nonspecific binding 
of proteins, and finally, an inappropriate blocking agents can inactivate the biomolecules. 
4.1.2. Sequence-Specific DNA-Directed Immobilization of Proteins 
Strategies for the sequence-specific DNA-directed immobilization of proteins (i.e., antibodies, 
enzymes, peptides, etc.) include two main approaches, the immobilization of protein-DNA conjugates on 
a complementary DNA-modified surface and the immobilization of proteins harboring a DNA-binding 
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domain on the cognate DNA-coated sensing layer. These DNA-directed immobilization techniques  
can orient proteins on a DNA chip surface in a manner that would allow the high binding affinity and 
specificity of proteins to their targets. Addressable biosensor chips using the site-direct immobilization of  
protein-DNA conjugates on a DNA-functionalized sensing layer have been developed [94–96]. 
Streptavidin-DNA conjugates have been used as molecular linkers in the DNA-directed immobilization of 
biotinylated antibodies on the chip surface (Figure 5A,B) [97]. In addition, DNA-linked antibodies have 
been applied onto a gold surface modified with complementary DNA (Figure 5C) [98]. The drawback of 
using antibody-DNA conjugates for DNA-directed immobilization is that labeling of antibodies with DNA 
molecules by covalent modification may have significant effects on their functional properties, that is, their 
abilities to bind antigens. 
 
Figure 5. Schematic representation of DNA-directed immobilization. (A) Conjugation of 
four covalent conjugates (HA-HD) with the biotinylated antibodies anti-carcinoembryonic 
antigen (RAC), anti-ceruloplasmin (SAC), anti-complement-1-inactivator (SCI), and  
anti-lectin (GAL) to generate capture reagents A-RAC, B-SAC, C-SCI, and D-GAL. 
Adapted from [97]; (B) Conjugation of Streptavidin-Cy5 with biotinylated RAC, SAC, SCI 
and GAL for the use of a microscaled fluorescence immunoassay. Adapted from [97];  
(C) DNA-directed immobilization of DNA-linked antibodies. c-A (Target sequence 
conjugated to anti-hCG): 5'-AGC GGA TAA CAA TTT CAC ACA GGA-3'; c-B (Target 
sequence conjugated to anti-hLH): 5'-AAC AGC TAT GAC CAT GAT TAC-3'; OEG, oligo 
(ethylene glycol). Adapted from [98]. 
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Studies on the DNA-binding domain-mediated immobilization of proteins on a consensus  
DNA-modified surface have been reported [99]. Likewise, Jeong et al. adopted the site-specific 
immobilization of proteins using sequence-specific DNA-binding domains for developing a protein 
microarray, which is a high-throughput tool for proteomics [100]. One representative tool for the 
characterization of protein-DNA interactions is SPR sensing. Sequence-specific interactions of the  
c-Myb protein with its specific sequences of DNA [101], and the p53 transcription factor with its 
consensus DNA binding sequences using SPR techniques have been reported [65]. DNA-binding 
domain-mediated protein immobilization on a cognate DNA-coated thin layer has applications in the  
on-chip profiling of transcription factor binding sites as well as the on-chip screening of protein-protein 
interactions between DNA-binding proteins and their interactants. 
4.1.3. Affinity Interactions 
The affinity capturing strategy is based on the modification of the sensor chip to capture special  
tag-conjugated proteins. Ligands are linked to the surface and function as bait, and they are used to 
attract targets, such as affinity tag-fused protein. In general, affinity interaction utilizes the specific 
interactions between ligands and affinity tags, providing the uniform and oriented immobilization of 
target proteins. One example is the interaction between biotin (vitamin B7) and streptavidin (tetrameric 
glycoprotein, 4 × 13 kDa), which has been widely used as a non-covalent affinity immobilization 
technique to bind biomolecules to the sensor chip surface. Streptavidin-tagged proteins can strongly and 
rapidly interact with a biotin-functionalized surface [102]. They are also used to bridge the biotin-coated 
layer and the biotinylated biomolecules [103]. Affinity fusion tags, such as glutathione S-transferase 
(GST) specific for glutathione, maltose binding protein (MBP) for amylose, hexahistidine (6ХHis) for 
Ni-NTA, and so on have been used in a wide range of biological applications including the detection, 
purification, and immobilization of recombinant proteins. DNA encoding an affinity tag can be 
genetically combined with the protein gene of interest. With affinity fusion strategies, the simple and 
fast analysis of recombinant proteins (i.e., GST-, MBP-, and 6ХHis-tagged proteins) expressed in E. coli 
has been carried out using an SPR imaging device [104]. To control the orientation of the immobilized 
antibody, genetically engineered protein G with various affinity tags such as 6ХHis [105], GST [106], 
elastin [107], and DNA molecules [108] has been developed. Even if the Ni-NTA-6ХHis linkage exhibits 
a weaker binding affinity than the biotin-streptavidin complex, hexahistidine-mediated affinity interaction 
based on the concept of immobilized-metal ion affinity chromatography (IMAC) is one of the most 
promising methods for the orientation-controlled immobilization of proteins, since the functional 
properties of the tagged proteins are only slightly hindered by the small size of 6ХHis tag. Instead, some 
tagged proteins with large size affinity tags, such as GST (~25.6 kDa) or MBP (~40.6 kDa) can cause 
considerable steric hindrance, which may lead to the loss of structural integrity and biological activity of 
the affinity fusion partners. 
4.1.4. S-Au Bond in Cysteine-Gold Clusters 
Immobilization with unidirectional orientation is used to eliminate unevenly distributed complexes 
induced by random covalent coupling chemistries, thus developing a potent biosensor with high 
sensitivity and specificity. The high affinity between gold and sulfur-containing biomolecules is a  
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well-known interaction concept for unidirectional immobilization. The orderliness in the SAM and 
molecular orientation can be achieved through S-Au binding, also referred to as the thiolated gold bond, 
involving the thiol (-SH) functional group. Cysteine residues have been widely used to immobilize 
proteins or peptides on an SPR gold surface for the purpose of controlled immobilization. With the 
advent of recombinant protein techniques, it is possible to express and purify a fusion protein containing 
cysteine amino acids with the ease of preparation of the cysteine-modified protein. [109]. The direct 
immobilization method has some important benefits such as speed, simplicity, favorable orientation, and 
increased functionality. Recently, the antibody-binding protein (ABP)-mediated immobilization of 
antibodies on a SPR surface has been carried out [110]. As shown in Figure 6, protein G, which 
specifically binds to the antibody Fc region, has been genetically modified with cysteine residues to 
immobilize antibodies on gold surfaces in an orientation-controlled manner, as antigen binding sites 
remain upright for undisturbed access of antigen to the antibodies, resulting in enhanced sensing 
performance. Well-oriented antibody immobilization based on cysteine-modified protein G does not 
hinder the active sites of the antibodies in response to an antigen; thus, the antibody activity on the 
biosensor surface is unaffected. This type of well-oriented, rather than randomly-oriented, 
immobilization demonstrates the enhanced antigen binding capacity of antibodies, allowing high 
sensitivity of antigen detection. Nevertheless, the use of protein G has a minor disadvantage that 
antibodies can be dissociated from the Fc region under certain conditions, such as low pH (2.0~3.0), 
leading to weaker signals. 
 
Figure 6. Schematic representation of direct immobilization of antibodies genetically 
modified with cysteines on a gold surface. A series of protein Gs containing two repeated 
IgG binding domains (B1 and B2) and a various numbers of cysteine amino acids, (Cys)1, 
(Cys)2, and (Cys)3, were genetically constructed, expressed/purified from E. coli, and 
subsequently analyzed using SPR biosensor. Adapted from [110]. 
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4.2. SPR Signal Amplification 
4.2.1. Metal Nanoparticles 
Metallic nanoparticles, especially gold nanoparticles (Au NPs), have been widely used to improve 
SPR-based sensing performance over the last decade. They are employed both in sensing surface 
enhancement and as amplification tags. Nanoparticle amplification tags are based on the fact that, upon 
addition of linked Au NPs, a pseudo mass increase of analyte is induced. This mass change finally 
produces higher refractive index changes on the SPR surface. In the first such work by Lyon and 
colleagues [111], colloidal gold particles of various sizes (30–59 nm in diameter) were used to coat a  
47 nm-thick Au film. The results demonstrated that with increasing particle size, the limit of detection 
(LOD) and the maximum level of quantitation both decreased. In another work [112], Lyon et al. 
conjugated anti-human immunoglobulin (h-IgG) to Au NPs for a sandwich immunoassay to detect  
h-IgG. It was observed that as antibody-Au colloid conjugate was added, the signal was significantly 
amplified by as much as 25 times. A 6.7 pM detection limit of h-IgG was achieved using this method 
(Figure 7). In addition to Au NPs, other metal nanoparticles including Ag NPs, SiO2 NPs [113], Pd  
NPs [114], and Pt NPs [17] have also been applied to increase SPR sensitivity in various biomolecular 
detection applications. 
 
Figure 7. Schematic diagram of an immunochemical molecular recognition to illustrate  
the utility of Au colloid-enhanced biosensing. Two strategies for particle-enhanced SPR 
immunosensing are described: (A) Direct binding of the antigen-Au complex to an  
antibody-modified surface; (B) Antibody-modified surface followed by binding of a free 
antigen and then a secondary antibody-Au conjugate. Adapted from [112]. 
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4.2.2. Magnetic Nanoparticles 
The use of magnetic nanoparticles (MNPs) has a history of a few decades in bioseparation but not 
long in bioassays. These materials have attracted a great deal of attention due to their advantages, such 
as higher surface-to-volume ratio, minimum disturbance to attached biomolecules, faster binding rates, 
higher miscibility, and higher specificity. Compared to other plasmonic nanoparticles, MNPs are more 
cost effective. Thus, MNPs could facilitate SPR surface immobilization and sample precipitation by the 
use of a magnetic field [115]. In 2009, Soelbert et al. developed a method for the rapid and sensitive 
detection of Staphylococcal enterotoxin B (SEB) using antibody-coated magnetic nanobeads. The 
magnetic characteristics of the beads were utilized for SEB purification and concentration from real 
complex matrices before the samples were allowed to flow into their miniature SPR system (Figure 8). 
An LOD of 100 picograms/mL for SEB was achieved in both buffer and stool samples. 
 
Figure 8. Strategy for detecting SEB in buffer and stool using antibody-coated  
magnetic nanobeads. (A) Steps for processing samples with colloidal immunomagnetic 
beads (antibody-coated superparamagnetic nanobeads). Anti-SEB antibody-modified 
nanobeads were mixed with solutions containing the target antigen (SEB) prior to the SPR 
measurement; (B) SPR detection of staphylococcal enterotoxin B (SEB) in buffer (663 RIU), 
in stool (365 RIU), and unprocessed (7 RIU). Adapted from [115]. 
4.2.3. Carbon-Based Nanomaterials 
Nanomaterials in this group, such as grapheme carbon nanotubes have also been employed to assist 
SPR biosensor signal enhancement. Since the discovery of graphene in 2004, researchers have developed 
an enormous number of graphene applications in biomolecular detection and analysis. In 2010, study on 
SPR signal amplification using grapheme-coated gold sensing film was introduced [116]. Wu et al. 
modified the sensing substrate (conventionally gold film) by coating multiple graphene sheets over the 
gold thin film (Figure 9). Graphene is a known two-dimensional material with novel properties. One of 
the properties that make it useful in SPR signal enhancement is its super-speed electron transport at room 
temperature. The charge transfer from the surface of graphene to the surface of the Au thin film makes 
the sensing surface more sensitive to changes in the sensing medium. This is due to the strong excited 
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electric field that exists on the surface of the Au thin film due to the graphene. The SPR signal was 
enhanced by as much as 25% when there were 10 graphene layers. 
 
Figure 9. The configuration of the proposed graphene-on-gold surface plasmon resonance 
biosensor based on generalized N-Layer model, where the gold film is deposited on top of a 
SF10 glass prism. A polychromatic light wave passes through the prism and is internally 
reflected on the prism-gold interface, creating an evanescent wave which penetrate the metal 
film (50 nm) and propagate along the x direction with propagation constant. The light 
propagation constant matches the surface plasmon polariton (SPP) propagation constant 
across the interface by controlling the incident angle θ. Plots of totally reflected intensity 
versus incident angle yield a peak, which is known as SPR angle. The graphene-on-gold 
surface plasmon resonance: prism | Au (50 nm) | graphene (L × 0.34 nm) | sensing medium, 
where L is the number of graphene layers, and Z0 = 100 nm is the thickness of the 
biomolecule layer. Adapted from [116]. 
For optimal amplification, many authors have coupled multiple types of nanomaterials in their design 
so as to benefit from both sensing substrate enhancement and amplification tags. Examples include 
graphene oxide (GO) and gold nanorod (AuNR)–antibody conjugates [117], graphene oxide coupled with 
gold nanoparticles [118], multiple layers of graphene, and silicon on gold thin film [119]. In a publication 
by Lee [120], carbon nanotubes (CNTs) conjugated with a poly-clonal antibody were employed for the 
detection of human erythropoietin (EPO) and human granulocyte macrophage colony-stimulating factor 
(GM–CSF) in a sandwich assay format. The results showed that the signal obtained by this CNTs 
amplification tags were 30 times higher than those of a direct antibody-antigen scheme. 
4.2.4. Other Approaches 
Despite the benefits of nanoparticles, there are also drawbacks of using them; for example, the 
synthesis and tuning steps are time and reagent-consuming. As SPR-based detection is heavily dependent 
on the mass change of the analytes in the sensing medium, researchers have tried to achieve signal 
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amplification using biochemical approaches in combination with nanoparticles. Examples include 
rolling circle amplification (RCA) [121,122], hybridization chain reaction (HCR) [123–125], DNA 
manipulation driven [126–128], strand displacement amplification (SDA) [129,130], bio barcode 
techniques [131]. As an example, a multi-step amplification scheme using an integrative approach from 
hybridization chain reaction (HCR), magnetic beads, and strand displacement for the detection of DNA 
and ATP was developed recently by Li et al. (Figure 10) [123]. The strategy allows a linear detection 
range of DNA from 0.5 to 500 fM with a detection limit of 0.3 fM, which is quite impressive in 
comparison to other techniques. Furthermore, the strategy allows surface regeneration without loss of 
specificity (94.2% after 5 regenerations), and it could also be used to detect ATP in the range of 1.0 to 
5000 nM with an LOD of 0.48 nM. 
 
Figure 10. SPR assay for ATP detection amplified by DNA-based hybridization  
chain reaction (HCR). (A) The S1-magnetic bead conjugates were prepared by direct 
immobilization of an amine-modified ATP aptamer linked to an activated carboxylate group 
on magnetic beads through the EDC/NHS chemistry, and then hybridized with its 
complementary oligonucleotide S2; (B) The strategy of continuous SPR monitoring of 
trigger DNA on a DNA chip array. Following a magnetic separation from the solution, the 
gold surface, on which the thiolated capture DNA was immobilized through S-Au bond, was 
treated with the sample containing S2. The released S2 functioned as trigger DNA to bind to 
the cohesive end of H1 in the presence of ATP. Adapted from [123]. 
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5. Recent Advances of SPR Technology 
Even though SPR imaging (SPRI) has been considered as a powerful tool for monitoring or screening 
of biomolecular binding events in a label-free manner, SPRI using the prism configuration remains 
inherent limitations, which come from the physical constraint of the prism as it limits the numerical 
aperture (NA) and magnification of an imaging system, thus providing poor spatial resolution.  
For example, a SPR system which uses a 0.1 NA prism substrate could only give ~3 µm imaging 
resolution of the lens at a wavelength of 633 nm. In addition, in prism-type SPR, due to the relative 
movement between sample and camera, acquired images is caused to move and suffered from a 
distortion by the prism when the incident angle scanning is performed. This restraint entangles the data 
analysis and lowers the spatial resolution of the obtained SPR curve. 
Recently, an alternative approach so-called high resolution SPR imaging that could correct all of the 
above addressed problems and offer a spatial resolution near the optical diffraction limit of the incident 
light has been developed [132–134]. Firstly proposed in 2007 by Huang et al. [133], an optical 
microscope objective-based SPR system built on the basis of the Kretschmann configuration using a 
high numerical aperture oil immersion objective and an inverted microscope has been successfully 
exploited in some critical applications such as single molecule analysis, or optical mapping (Figure 11). 
 
Figure 11. General principle of the objective-type SPRI setup. The optical configuration of 
the SPR microscope. Adapted from [133].  
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A major superiority of objective-type SPRI is that the sample and imaging optical paths are fixed 
throughout incident angle scanning. Thus, it permits a pixel-by-pixel tracking of the reflectivity in the 
SPR images. Each of these pixels accordingly produces a SPR curve and the image is framed using the 
SPR minimum angle information. Following this approach, variations such as inhomogeneity and 
unwanted interferences from the laser intensity could be significantly removed by using a homogeneous 
referencing surface. More importantly, the divergence in incident angles at different spots of the image 
field caused by the abnormality of the objective lens could be corrected as well. Firstly, the use of a high 
NA and high magnification imaging system could provide a diffraction limit resolution (~300 nm) for 
the imaging optics [133]. Providing that SPR occurs at a larger angle than the critical angle, the 
immersion objective is chosen to have a NA (such as an Olympus 1.65 NA objective) which is larger 
than the refractive index of the medium. Consequently, when the incident light is transferred to the 
objective back aperture edge, it will arrive at the sample surface at an angle that is greater than the critical 
angle. Additionally, the angle coverage is also increased by this high NA objective. Secondly, compared 
to the angle scanning mode in a conventional SPR measurement, the use of an objective lens could 
simplify the system design by converting the rotational motion of the incident light at the sample into 
linear motion of the stage. Hence, it helps improve the overall mechanical performance of the system. 
Taking advantage of the advanced SPRI new capabilities, researchers have successfully employed 
this high-spatial resolution SPR in imaging and detection of single DNA molecules [135], virus [136], 
cells [137]. Plus, single cell-substrate interactions mapping [137] and direct binding kinetics of  
proteins-cell membrane proteins mapping [138] were also made possible using this innovative system. 
The recent advances in plasmonic imaging technique using high-resolution surface plasmon resonance 
microscopy (SPRM) approach would undoubtedly have extensive impacts on the quantitative analysis 
of intracellular dynamics in live cells, single molecule analysis and the studies of the biological activities 
of membrane proteins as well as the discovery of new drugs that target membrane proteins. 
6. Conclusions 
SPR-based biosensor applications extend beyond the scope of this review paper. The SPR technique 
has been proven to be one of the most versatile frameworks for biosensors applications in the most 
concerning medical, biology, environment, and food safety areas. SPR biosensors provide excellent 
analytical performance in terms of high sensitivity, fast response, LOD and reproducibility with its  
label-free, real-time approach. However, one challenge for SPR technology, which was raised in 2008 
by Schasfoort and Schuck about its suitability for point-of-care (POC) diagnostics [139], has not been 
completely solved. The inherent drawback of SPR lies in the interference of non-specific bindings to the 
outcome signals. Additionally, the kinetic rate and equilibrium constants data for biomolecular 
interactions obtained by SPR biosensors have low significance in POC analysis. Given the growing trend 
of applying biosensors in point-of-care testing (POCT), which is often performed by using portable and 
hand-held devices, SPR technology is one of the most promising tools because it is continuously 
progressing and evolving to be more suitable for user-friendly hand-held devices [69,140,141]. POCT 
is an important issue in settings where timing is critical (i.e., emergency care or disease outbreaks). To 
meet this growing need for SPR devices that can be deployed in the field, every effort is being made to 
build more affordable, more accessible, and more applicable SPR sensor products. Clearly, a portable 
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SPR system offers s strong potential for POCT applications related to security and defense against 
bioterrorism by detecting pathogenic species and identifying toxins in water in areas with no access to 
laboratory facilities. However, current SPR instruments are still bulky and costly, and this remains as an 
obstacle to the commercialization of SPR technology. In the coming years, more research on the 
development of innovative chip chemistry and antifouling strategies in combination with amplification 
schemes and miniaturization are needed to make SPR an irreplaceable tool for routine clinical analysis 
and POC diagnostics. 
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